05:14 PM EST, 02/27/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported a Q4 net loss late Thursday of $0.88 per diluted share, narrowing from the loss of $0.90 a year earlier.

Analysts polled by FactSet expected a loss of $0.89.

No revenue was reported for the quarters that ended Dec. 31 in 2023 and 2024. Analysts surveyed by FactSet projected $700,000 in Q4 2024.

As of Dec. 31, the company had $1.4 billion in cash, cash equivalents and investments, enough to fund the current operating plan into 2029.